8 reports

Lilly will continue to pursue medicines that use the body' s immune system in new ways to treat cancer and that have the potential to make a meaningful difference to patients with cancer.

  • Market Size
  • Alkermes plc
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

CANCER MORTALITY FOR SELECTED SITES IN ## COUNTRIES (1950-##).

  • Alkermes plc
  • Allergan plc
  • Janssen Biotech, Inc.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.

Cancer and Prostatic Diseases; ##(##): ##-##.

  • Alkermes plc
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Deal Rationale
  • Deal Rationale

ALKS ##: Preclinical data on ALKS ## was presented at the Society of Immunotherapy of Cancer (SITC) Annual Meeting.

  • Pharmaceutical
  • Therapy
  • United States
  • Company Financials
  • Alkermes plc
  • 5. All the trials included are unique trials.

Component ##.

  • Addiction Disorder
  • Antiseptics
  • Clinical Trial
  • Therapy
  • Alkermes plc
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

Component ##.

  • Addiction Disorder
  • Antiseptics
  • Neurology
  • Therapy
  • Alkermes plc
  • PARTNERSHIP

The company develops drugs for breast and ovary cancer, prostate cancer, the lymphomas and acute myeloid leukemia.

  • Pharmaceutical
  • Therapy
  • United States
  • Corporate Finance
  • Alkermes plc
  • COMPANY INFORMATION: PARTNERS
  • COMPANY INFORMATION: PARTNERS

The company develops compounds for the treatment of overactive bladder, male hypogonadism, prostate and bladder cancer, central precocious puberty, and the prevention of infection by HIV, and other sexually transmitted pathogens.

  • Pharmaceutical
  • Therapy
  • Company
  • M&A
  • Alkermes plc